Scientists identify Arc protein's role in spreading Alzheimer's pathology

Alzheimer's disease kills by stealth. A toxic protein called Tau begins clumping inside neurons, forming sticky tangles that choke off the cell's ability to function. As these tangles spread from one region of the brain to another, the disease tightens its grip—symptoms worsen, cognition fades, and eventually the disease becomes fatal. For decades, researchers have understood that Tau spreads, but the mechanism remained opaque. Now scientists have identified the courier: a brain protein called Arc that acts as a cellular ferry service, wrapping toxic Tau in microscopic bubbles and shuttling it from dying neurons to healthy ones.

The discovery emerged from work in mouse models of Alzheimer's disease conducted by researchers at the University of Utah and Washington University in St. Louis. Jason Shepherd, a neurobiology professor at Utah, led the team in studying how Arc functions in the diseased brain. What they found was both illuminating and troubling. Arc normally serves a benign purpose—it packages itself into tiny vesicles, bubble-like structures that float between brain cells carrying vital information. But in Alzheimer's disease, toxic Tau hitches a ride on these vesicles, traveling from one neuron to the next like a parasite using a host's transportation system.

Mitali Tyagi, the first author on the paper, describes Tau tangles as "glue monsters." They bind together and jam up the neuron's internal machinery. But they can also fragment into smaller pieces called Tau seeds, which are far more dangerous. When a Tau seed reaches a healthy neuron, it corrupts the normal Tau already present there, triggering the formation of new tangles. The pathology restarts in virgin territory. In the mouse models, the researchers found extracellular vesicles—those Arc-wrapped bubbles—loaded with both Arc and sticky Tau. These tiny packages could infect healthy cells and initiate the cascade all over again.

But here is where the science becomes complicated. When the researchers removed Arc entirely from the mice, something unexpected happened. The transfer of Tau between cells nearly stopped. The disease could no longer spread. Yet the mice with no Arc did not fare better. Instead, their neurons died faster. Arc, it turned out, was also protective. By ejecting excess toxic Tau from sick cells, Arc allowed those neurons to survive longer. Without Arc, Tau accumulated to lethal levels inside the cell, and the neuron perished more quickly. Blocking Arc entirely would accelerate the very damage researchers hoped to prevent.

This paradox points toward a more nuanced therapeutic strategy. Rather than eliminating Arc, future treatments might intercept Tau-laden vesicles in transit—after they leave a sick cell but before they reach a healthy one. Such an intervention would not repair existing brain damage, but it could halt the disease's progression. For someone in the early stages of Alzheimer's, stopping the spread of Tau could prevent further cognitive decline and buy time.

The research, published in the journal Cell, offers a crucial proof of concept. The team found that human brain tissue also contains vesicles carrying both Arc and Tau, suggesting the mechanism operates in people much as it does in mice. But Shepherd is careful about expectations. Most of the work remains in animal models. The leap from mouse to human is substantial, and the distance from laboratory discovery to clinical therapy is vast. "We're far away from saying that we're developing a treatment," he acknowledges. Yet the pathway is now visible. If therapies can be designed to target these traveling vesicles, they could become a powerful tool to slow or stop Alzheimer's disease in its tracks.